Literature DB >> 11960356

Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link.

F Kuttler1, M B Valnet-Rabier, R Angonin, C Ferrand, E Deconinck, C Mougin, J Y Cahn, T Fest.   

Abstract

Accumulating evidence suggests that lack of balance between proliferation and apoptosis may lead to clonal expansion and cancer emergence. In diffuse large B cell lymphoma (DLBCL), survivin expression by tumor cells has been recently described as a poor prognostic marker. We assessed the relationship between survivin gene up-regulation and several other factors involved in either cell cycle or apoptosis control. The expression of 34 genes from 27 cases of DLBCL with typical IPI factor-related poor prognostic outcome was analyzed by RNase protection assay. Using non-neoplastic tissues and low grade lymphomas as control, survivin expression was high in 80% of the cases without significant relation to patient overall survival (P = 0.64). However, the expression of several genes encoding for cell cycle inhibitors, cyclins, Bcl-2 or IAP family factors was significantly associated with the survivin up-regulation. Gene expression profiling showed that both survivin and cyclin B expression can define two subgroups of DLBCL: the previously described germinal center-like and activated B-like lymphomas, determined by protein expression analysis. We also identified a preferential survivin-cyclin B relationship (P = 0.017), suggesting that cyclin B over-expression, when linked to survivin over-expression in aggressive forms of lymphoma, might demonstrate a specific G2/M transition promotion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960356     DOI: 10.1038/sj.leu.2402427

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections.

Authors:  José Vassallo; Talal Al Saati; Randy D Gascoyne; Kathyrn Welsh; John C Reed; Pierre Brousset; Georges Delsol
Journal:  J Hematop       Date:  2010-01-30       Impact factor: 0.196

2.  Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma.

Authors:  Yunguang Sun; Nicholas J Giacalone; Bo Lu
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

3.  A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score.

Authors:  Sylvia Höller; Heike Horn; Andreas Lohr; Uwe Mäder; Tiemo Katzenberger; Jörg Kalla; Heinz-Wolfram Bernd; Philip Went; M Michaela Ott; Hans Konrad Müller-Hermelink; Andreas Rosenwald; German Ott
Journal:  J Hematop       Date:  2009-09-02       Impact factor: 0.196

4.  Do Bcl-2 and survivin help distinguish benign from malignant B-cell lymphoid aggregates in bone marrow biopsies?

Authors:  Amish M Gandhi; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 5.  Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.

Authors:  Ronan J Kelly; Ariel Lopez-Chavez; Deborah Citrin; John E Janik; John C Morris
Journal:  Mol Cancer       Date:  2011-04-06       Impact factor: 27.401

6.  Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.

Authors:  Alexandar Tzankov; Philip Went; Stephan Dirnhofer
Journal:  Biomark Insights       Date:  2007-11-11

7.  Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis.

Authors:  Sofia E M Andersson; Mattias N D Svensson; Malin C Erlandsson; Mats Dehlin; Karin M E Andersson; Maria I Bokarewa
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.